This paper aims to propose an update on therapeutic medical options for malignant pleural mesothelioma
2017
Key concepts
Scholarcy highlights
- The key challenge remains to find reliable predictive biomarkers for these innovative, exciting, and expensive treatments to select the best patients for each strategy
- Arnaud Scherpereel reports grants from Roche SA and was the principal investigator of clinical trials supported by Roche
- This article does not contain any studies with human or animal subjects performed by any of the authors
- This article is part of the Topical Collection on Pleural Diseases and Mesothelioma
Need more features? Save interactive summary cards to your Scholarcy Library.